Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing

Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing RESEARCH ARTICLE Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing Hollis Viray, BS,* Madeline Coulter,* Kevin Li,* Kristin Lane, BS,w Aruna Madan, MD,* Kisha Mitchell, MD,* Kurt Schalper, MD, PhD,* Clifford Hoyt, PhD,w and David L. Rimm, MD, PhD* 1,2 spond to those therapies. DNA mutation status and Abstract: Detection of DNA mutations in tumor tissue can be a patient genotypes can be indicators of patient treatment critical companion diagnostic test before prescription of a tar- 3,4 response for some targeted therapies. For example, for geted therapy. Each method for detection of these mutations is the treatment of patients with advanced colorectal cancer, associated with an analytic sensitivity that is a function of the K-ras mutation status has been shown to predict non- percentage of tumor cells present in the specimen. Currently, response to epidermal growth factor receptor (EGFR) tumor cell percentage is visually estimated resulting in an ordi- 1,5–8 inhibitors. The K-ras protein is a downstream target nal and highly variant result for a biologically continuous var- 9 of EGFR signaling. As a downstream protein in the iable. We proposed that this aspect of DNA mutation testing EGFR signaling pathway, a mutated and constitutively could http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing

Loading next page...
 
/lp/wolters-kluwer-health/automated-objective-determination-of-percentage-of-malignant-nuclei-eXZQ8ScaiA
Copyright
Copyright © 2013 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e318299a1f6
pmid
24162261
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing Hollis Viray, BS,* Madeline Coulter,* Kevin Li,* Kristin Lane, BS,w Aruna Madan, MD,* Kisha Mitchell, MD,* Kurt Schalper, MD, PhD,* Clifford Hoyt, PhD,w and David L. Rimm, MD, PhD* 1,2 spond to those therapies. DNA mutation status and Abstract: Detection of DNA mutations in tumor tissue can be a patient genotypes can be indicators of patient treatment critical companion diagnostic test before prescription of a tar- 3,4 response for some targeted therapies. For example, for geted therapy. Each method for detection of these mutations is the treatment of patients with advanced colorectal cancer, associated with an analytic sensitivity that is a function of the K-ras mutation status has been shown to predict non- percentage of tumor cells present in the specimen. Currently, response to epidermal growth factor receptor (EGFR) tumor cell percentage is visually estimated resulting in an ordi- 1,5–8 inhibitors. The K-ras protein is a downstream target nal and highly variant result for a biologically continuous var- 9 of EGFR signaling. As a downstream protein in the iable. We proposed that this aspect of DNA mutation testing EGFR signaling pathway, a mutated and constitutively could

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2014

There are no references for this article.